DongKoo Bio & Pharma Statistics

Total Valuation

DongKoo Bio & Pharma has a market cap or net worth of KRW 137.33 billion. The enterprise value is 183.36 billion.

Market Cap	137.33B
Enterprise Value	183.36B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

DongKoo Bio & Pharma has 27.30 million shares outstanding. The number of shares has decreased by -0.44% in one year.

Current Share Class	n/a
Shares Outstanding	27.30M
Shares Change (YoY)	-0.44%
Shares Change (QoQ)	-0.86%
Owned by Insiders (%)	43.81%
Owned by Institutions (%)	0.66%
Float	15.23M

Valuation Ratios

The trailing PE ratio is 10.66.

PE Ratio	10.66
Forward PE	n/a
PS Ratio	0.58
PB Ratio	1.22
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.35, with an EV/FCF ratio of -11.87.

EV / Earnings	14.10
EV / Sales	0.76
EV / EBITDA	9.35
EV / EBIT	13.73
EV / FCF	-11.87

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.62.

Current Ratio	0.93
Quick Ratio	0.47
Debt / Equity	0.62
Debt / EBITDA	3.52
Debt / FCF	-4.49
Interest Coverage	6.28

Financial Efficiency

Return on equity (ROE) is 11.94% and return on invested capital (ROIC) is 5.20%.

Return on Equity (ROE)	11.94%
Return on Assets (ROA)	4.17%
Return on Capital (ROIC)	5.20%
Revenue Per Employee	641.05M
Profits Per Employee	34.68M
Employee Count	375
Asset Turnover	1.19
Inventory Turnover	2.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-10.51%
50-Day Moving Average	5,616.60
200-Day Moving Average	6,259.30
Relative Strength Index (RSI)	38.48
Average Volume (20 Days)	156,300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DongKoo Bio & Pharma had revenue of KRW 240.39 billion and earned 13.00 billion in profits. Earnings per share was 471.99.

Revenue	240.39B
Gross Profit	145.93B
Operating Income	13.47B
Pretax Income	15.94B
Net Income	13.00B
EBITDA	19.73B
EBIT	13.47B
Earnings Per Share (EPS)	471.99

Full Income Statement

Balance Sheet

The company has 23.50 billion in cash and 69.39 billion in debt, giving a net cash position of -45.90 billion or -1,681.09 per share.

Cash & Cash Equivalents	23.50B
Total Debt	69.39B
Net Cash	-45.90B
Net Cash Per Share	-1,681.09
Equity (Book Value)	112.57B
Book Value Per Share	4,118.28
Working Capital	-6.74B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 11.76 billion and capital expenditures -27.21 billion, giving a free cash flow of -15.45 billion.

Operating Cash Flow	11.76B
Capital Expenditures	-27.21B
Free Cash Flow	-15.45B
FCF Per Share	-565.89

Full Cash Flow Statement

Margins

Gross margin is 60.71%, with operating and profit margins of 5.60% and 5.41%.

Gross Margin	60.71%
Operating Margin	5.60%
Pretax Margin	6.63%
Profit Margin	5.41%
EBITDA Margin	8.21%
EBIT Margin	5.60%
FCF Margin	-6.43%

Dividends & Yields

This stock pays an annual dividend of 120.00, which amounts to a dividend yield of 2.45%.

Dividend Per Share	120.00
Dividend Yield	2.45%
Dividend Growth (YoY)	9.09%
Years of Dividend Growth	3
Payout Ratio	25.47%
Buyback Yield	0.44%
Shareholder Yield	2.89%
Earnings Yield	9.38%
FCF Yield	-11.25%

Dividend Details

Stock Splits

The last stock split was on March 2, 2021. It was a forward split with a ratio of 3.

Last Split Date	Mar 2, 2021
Split Type	Forward
Split Ratio	3

Scores

DongKoo Bio & Pharma has an Altman Z-Score of 2.53. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.53
Piotroski F-Score	n/a